|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
modulation of neurotransmitter release
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
gptkb:Dr._Johnson
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:category
|
gptkb:drug
|
|
gptkbp:class
|
pyridine derivative
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:USA
moderate
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
gptkb:Research_Institute
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:financial_performance
|
high stability
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0682
|
|
gptkbp:indication
|
cognitive enhancement
|
|
gptkbp:ingredients
|
C20 H22 N2 O2
|
|
gptkbp:invention
|
gptkb:Allergan
patented
|
|
gptkbp:investment
|
Alzheimer's treatment
|
|
gptkbp:is_a_source_of
|
synthetic origin
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of cognitive disorders
|
|
gptkbp:lifespan
|
4 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
not yet marketed
|
|
gptkbp:material
|
stable under normal conditions
lipophilic
non-polar
|
|
gptkbp:project
|
preclinical
|
|
gptkbp:receives_funding_from
|
private investment
government grant
|
|
gptkbp:related_to
|
gptkb:psychologist
|
|
gptkbp:research
|
ongoing studies
promising results
|
|
gptkbp:research_areas
|
gptkb:University_of_California
gptkb:psychologist
neurology
neuropharmacology
|
|
gptkbp:research_focus
|
cognitive decline
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
insomnia
dry mouth
|
|
gptkbp:social_structure
|
complex organic structure
|
|
gptkbp:status
|
under investigation
|
|
gptkbp:targets
|
gptkb:α7_nicotinic_receptor
gptkb:Nicotinic_acetylcholine_receptor
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:was_a_response_to
|
low reactivity
|
|
gptkbp:weight
|
310.4 g/mol
|
|
gptkbp:year_created
|
gptkb:2015
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|